Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHS-1000 alone and with toripalimab in advanced solid tumors
NCT06389526Phase 1Not yet recruiting
- Sponsor
- Coherus BioSciences, Inc.
- Start
- Feb 2025
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of CHS-1000 in solid tumor (advanced stage) (2 arms), sponsored by Coherus BioSciences, Inc. Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events at 27 months. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
CHS-1000
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06389526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389526.